Literature DB >> 21464257

Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors.

Eric B Lansdon1, Qi Liu, Stephanie A Leavitt, Mini Balakrishnan, Jason K Perry, Candra Lancaster-Moyer, Nilima Kutty, Xiaohong Liu, Neil H Squires, William J Watkins, Thorsten A Kirschberg.   

Abstract

HIV-1 RNase H breaks down the intermediate RNA-DNA hybrids during reverse transcription, requiring two divalent metal ions for activity. Pyrimidinol carboxylic acid and N-hydroxy quinazolinedione inhibitors were designed to coordinate the two metal ions in the active site of RNase H. High-resolution (1.4 Å to 2.1 Å) crystal structures were determined with the isolated RNase H domain and reverse transcriptase (RT), which permit accurate assessment of the metal and water environment at the active site. The geometry of the metal coordination suggests that the inhibitors mimic a substrate state prior to phosphodiester catalysis. Surface plasmon resonance studies confirm metal-dependent binding to RNase H and demonstrate that the inhibitors do not bind at the polymerase active site of RT. Additional evaluation of the RNase H site reveals an open protein surface with few additional interactions to optimize active-site inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464257      PMCID: PMC3101433          DOI: 10.1128/AAC.01594-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  59 in total

Review 1.  HIV-1 integrase and RNase H activities as therapeutic targets.

Authors:  M L Andréola; V Richard De Soultrait; M Fournier; V Parissi; C Desjobert; S Litvak
Journal:  Expert Opin Ther Targets       Date:  2002-08       Impact factor: 6.902

2.  Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis.

Authors:  Marcin Nowotny; Sergei A Gaidamakov; Robert J Crouch; Wei Yang
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

Review 3.  HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target.

Authors:  Enzo Tramontano
Journal:  Mini Rev Med Chem       Date:  2006-06       Impact factor: 3.862

4.  Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription.

Authors:  Marcin Nowotny; Sergei A Gaidamakov; Rodolfo Ghirlando; Susana M Cerritelli; Robert J Crouch; Wei Yang
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

5.  Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.

Authors:  Eric B Lansdon; Katherine M Brendza; Magdeleine Hung; Ruth Wang; Susmith Mukund; Debi Jin; Gabriel Birkus; Nilima Kutty; Xiaohong Liu
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

6.  A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that is enzymatically active.

Authors:  D B Evans; K Brawn; M R Deibel; W G Tarpley; S K Sharma
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity.

Authors:  Michaela Wendeler; Hsiu-Fang Lee; Alun Bermingham; Jennifer T Miller; Oleg Chertov; Marion K Bona; Noel S Baichoo; Maryam Ehteshami; John Beutler; Barry R O'Keefe; Matthias Götte; Mamuka Kvaratskhelia; Stuart Le Grice
Journal:  ACS Chem Biol       Date:  2008-10-03       Impact factor: 5.100

9.  Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides.

Authors:  Julie Qi Hang; Surendran Rajendran; Yanli Yang; Yu Li; Philippe Wong Kai In; Hilary Overton; Kevin E B Parkes; Nick Cammack; Joseph A Martin; Klaus Klumpp
Journal:  Biochem Biophys Res Commun       Date:  2004-04-30       Impact factor: 3.575

10.  2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.

Authors:  Uwe Koch; Barbara Attenni; Savina Malancona; Stefania Colarusso; Immacolata Conte; Marcello Di Filippo; Steven Harper; Barbara Pacini; Claudia Giomini; Steven Thomas; Ilario Incitti; Licia Tomei; Raffaele De Francesco; Sergio Altamura; Victor G Matassa; Frank Narjes
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

View more
  39 in total

Review 1.  Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise.

Authors:  Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

2.  Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs.

Authors:  Daniel M Himmel; Nataliya S Myshakina; Tatiana Ilina; Alexander Van Ry; William C Ho; Michael A Parniak; Eddy Arnold
Journal:  J Mol Biol       Date:  2014-05-17       Impact factor: 5.469

3.  Synthetic α-Hydroxytropolones as Inhibitors of HIV Reverse Transcriptase Ribonuclease H Activity.

Authors:  Ryan P Murelli; Michael P D'Erasmo; Danielle R Hirsch; Christine Meck; Takashi Masaoka; Jennifer A Wilson; Baofeng Zhang; Rajat K Pal; Emilio Gallicchio; John A Beutler; Stuart F J Le Grice
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

4.  Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H.

Authors:  Zhaoyong Xi; Zhengqiang Wang; Stefan G Sarafianos; Nataliya S Myshakina; Rieko Ishima
Journal:  ACS Infect Dis       Date:  2019-10-02       Impact factor: 5.084

5.  Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity.

Authors:  Suhman Chung; Jennifer T Miller; Barry C Johnson; Stephen H Hughes; Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

6.  Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.

Authors:  Sanjeev Kumar V Vernekar; Jing Tang; Bulan Wu; Andrew D Huber; Mary C Casey; Nataliya Myshakina; Daniel J Wilson; Jayakanth Kankanala; Karen A Kirby; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  J Med Chem       Date:  2017-05-31       Impact factor: 7.446

7.  Inhibition of foamy virus reverse transcriptase by human immunodeficiency virus type 1 RNase H inhibitors.

Authors:  Angela Corona; Anna Schneider; Kristian Schweimer; Paul Rösch; Birgitta M Wöhrl; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

8.  Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives.

Authors:  Angela Corona; Francesco Saverio Di Leva; Sylvain Thierry; Luca Pescatori; Giuliana Cuzzucoli Crucitti; Frederic Subra; Olivier Delelis; Francesca Esposito; Giuseppe Rigogliuso; Roberta Costi; Sandro Cosconati; Ettore Novellino; Roberto Di Santo; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H.

Authors:  Jayakanth Kankanala; Karen A Kirby; Feng Liu; Lena Miller; Eva Nagy; Daniel J Wilson; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  J Med Chem       Date:  2016-04-29       Impact factor: 7.446

10.  Unfolding the HIV-1 reverse transcriptase RNase H domain--how to lose a molecular tug-of-war.

Authors:  Xunhai Zheng; Lars C Pedersen; Scott A Gabel; Geoffrey A Mueller; Eugene F DeRose; Robert E London
Journal:  Nucleic Acids Res       Date:  2016-01-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.